YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com -- Wells Fargo Securities named 13 stocks across seven sectors as its fourth-quarter 2026 long ideas, citing company-specific catalysts that could drive significant gains. Before you buy NVIDIA: our AI model's stock picks are…
The S&P 500 Index ($SPX) (SPY) is down -0.42% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.43%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.69%. E-mini S&P futures (ESU26) are down -0.40%, and September E-mini Nas…
The S&P 500 Index ($SPX) (SPY) is down -0.54% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.32%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.96%. E-mini S&P futures (ESU26) are down -0.50%, and September E-mini Nas…
It has been about a month since the last earnings report for Kymera Therapeutics, Inc. (KYMR). Shares have added about 10.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earn…
Kymera Therapeutics KYMR is leveraging targeted protein degradation, a next-generation small-molecule therapeutic modality that harnesses the body's natural cellular recycling system to selectively eliminate disease-causing proteins. The c…
Kymera Therapeutics, Inc. WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunol…
Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Kymera Therapeutics, Inc. Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with toplin…
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Founder, President and Chief Executive Officer - Nello MainolfiChief Financial Officer - Bruce JacobsChief Medical Officer - Terence RooneyVice P…
Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi (SNY), RBC Capital Markets said in a Monday research note.The invest…
Kymera Therapeutics, Inc. KYMR reported a second-quarter 2026 loss of 62 cents per share, narrower than the Zacks Consensus Estimate of a loss of 64 cents. The company posted a loss of 95 cents in the year-ago period. Revenues surged to $6…
Kymera Therapeutics, Inc. has reported past second-quarter 2026 results showing a reduced net loss of US$61.21 million and lower basic and diluted loss per share of US$0.62, while also completing Phase 2b enrollment for its KT-621 atopic d…
Key Points Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better. KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line Phase 2b data expected by the end of 2026 and…
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago. These figures are adjusted for non-recurring…
Kymera Therapeutics, Inc. Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT…
Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Eli Lilly and Company (LLY [https://seekingalpha.com/symbol/LLY]) * Shopify (SHOP [https://seekingalpha.c…
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as co…
Quick Read Iran conflict escalation, oil surging nearly 8%, and a semiconductor sell-off drove the Dow down 2% and Nasdaq down nearly 2% Wednesday. Goldman Sachs cut Fiverr (FVRR) to Neutral and slashed its target in half to $13, while Blo…
Kymera Therapeutics, Inc. WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunolo…
Kymera Therapeutics, Inc. Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight…
Key Points The State Street Health Care Select Sector SPDR ETF manages $41.7 billion in assets under management (AUM), providing significantly higher liquidity than the Fidelity MSCI Health Care Index ETF Fidelity MSCI Health Care Index ET…
Key Points The State Street Health Care Select Sector SPDR ETF manages $41.7 billion in assets under management (AUM), providing significantly higher liquidity than the Fidelity MSCI Health Care Index ETF Fidelity MSCI Health Care Index ET…
Kymera Therapeutics KYMR is leveraging targeted protein degradation (TPD), a next-generation small-molecule therapeutic modality that harnesses the body's natural cellular recycling system to selectively eliminate disease-causing proteins.…
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) breached their fiduciary duties to sharehol…
American Express, Biogen upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
Quick Read SK hynix surged 13% on its Nasdaq debut, raising $26.5 billion in what stands as the largest U.S. equity sale by a foreign company ever. Circle Internet Group (CRCL) surged 15% on OCC bank approval as Capital One (COF) earned a…
Key Points According to a Form 4, proceeds of approximately $6.0 million were realized from the exercise and immediate sale of 50,000 shares at $119.00 per share on July 7, 2026. The transaction reduced the insider's direct common stock ho…
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing. Transaction summary Metric Value Transaction value…
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 10 Best Performing American Stocks in June 2026. On June 30, 2026, BofA raised the firm's price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) to $125 from $110 and kept a Buy rating…
Kymera Therapeutics, Inc. Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 202…
Activist investors report to the SEC on Alkami Technology, Smith & Nephew, Navigator Holdings, Diebold Nixdorf, and Kymera Therapeutics. Continue Reading
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Kymera Therapeutics now carries an updated fair value estimate of US$123.76, a modest step up from US$119.19 that has drawn attenti…
In late June 2026, Kymera Therapeutics completed enrollment ahead of schedule in its global Phase 2b BROADEN2 trial of KT-621 for moderate to severe atopic dermatitis and was added to several Russell value and small-cap benchmarks, while a…
Kymera Therapeutics KYMR has put up a stupendous year-to-date performance. Shares of the company have gained 50.9% year to date compared with the industry's growth of 6.4%. Investors have become increasingly optimistic about its lead candi…
Key Points It completed the enrollment phase of a Phase 2b study of its leading drug candidate. This medication will be trialed to gauge its efficacy in treating severe atopic dermatitis.10 stocks we like better than Kymera Therapeutics ›…
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch of analyst price target raises. These dev…